Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$49.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Array Biopharma Inc Announces Positive Interim Results From Combination Trial Of Arry-520 With Kyprolis At The 2013 European Hematology Association Congress


Monday, 17 Jun 2013 08:00am EDT 

Array Biopharma Inc announced that interim results from an ongoing ARRY-520 clinical trial in multiple myeloma (MM) were presented at the 2013 Congress of the European Hematology Association in Stockholm, Sweden. Also at the meeting, Array presented updated information on a potential patient selection marker for ARRY-520. ARRY-520 is a selective, targeted inhibitor of KSP with a mechanism of action distinct from other drugs used to treat MM that continues to advance in clinical trials. Interim data from an ongoing combination trial of ARRY-520 with Kyprolis (carfilozomib) in patients with relapsed or refractory MM who are refractory or intolerant to Velcade (bortezomib) were reported. The combination has demonstrated early signals of activity with a disease control rate (complete response, partial response, minimal response or stable disease) of 82% and a clinical benefit rate (=minimal response) of 53%, including one complete response. In addition, the combination has been well tolerated with no unexpected hematologic toxicity and a manageable side effect profile. More than half of the patients enrolled remain on study, with patients in the current cohort receiving full doses of both drugs without reaching a maximum tolerated dose (MTD). Data on a potential patient selection marker was also presented from multiple studies of ARRY-520 in patients with relapsed and refractory multiple myeloma. 

Company Quote

8.25
-0.05 -0.60%
1:33pm EST